Results 281 to 290 of about 5,305,995 (318)

DDX3X induces mesenchymal transition of endothelial cells by disrupting BMPR2 signaling

FEBS Open Bio, EarlyView.
Elevated DDX3X expression led to downregulation of BMPR2, a key regulator of endothelial homeostasis and function. Our co‐immunoprecipitation assays further demonstrated a molecular interaction between DDX3X and BMPR2. Notably, DDX3X promoted lysosomal degradation of BMPR2, thereby impairing its downstream signaling and facilitating endothelial‐to ...
Yu Zhang, Jing Wang, De‐Hui Qian, Yang‐Fan Lv, Tian‐Le Cheng, Da‐Peng Wang, Jing Zhang, Ye Fan   +7 more
wiley   +1 more source

Therapy Allergen Ordinance (TAO): The final stretch. [PDF]

Allergol Select
Mahler V, Hartenstein D, Lauer I, Vieths S, Ruoff C, Zimmer J, Kaul S.   +6 more
europepmc   +1 more source

Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance. [PDF]

Nat Commun
Moon K, Coxon C, Årdal C, Botgros R, Djebara S, Durno L, Fiore CR, Perrin JB, Dixon DM, Cavaleri M.   +9 more
europepmc   +1 more source

Blockchain adoption in remanufacturing under carbon tax policies: A game theory analysis of industry dynamics and consumer impact. [PDF]

PLoS One
Li J, Yang T, Shi L.
europepmc   +1 more source

Reimagining Early-Phase Clinical Development in Japan: From Regulatory Obligation to Global Acceleration. [PDF]

Clin Transl Sci
Kawakita Y, Matsumoto K, Hirano M, Inoue S, Mashita O, Tawara H, Sato M.   +6 more
europepmc   +1 more source

The new product development process : small firm success by studying larger firms

, 2008
Wiehann Van Zyl
openalex   +1 more source

New Developments in the Nondestructive Testing of Quality for Industrial Products

, 2012
N. P. Migun
openalex   +1 more source

Patents and New Product Development in the Pharmaceutical and Biotechnology Industries [PDF]

Henry Grabowski
core